Page 45 - Priority Review News Today

Repotrectinib continued to demonstrate high response rates and durable responses, including robust intracranial responses, in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer who were TKI-naïve or previously treated with one TKI and no chemotherapyMedian duration of response and...

Bristol Myers Squibb announced updated results from the registrational TRIDENT-1 study, demonstrating that repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor , continued to show high... -Today at 10:19 am- MarketScreener

Bluebird bio, Inc. today announced that the U.S. Food and Drug Administration has communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel . Lovo-cel is... -Today at 07:01 am- MarketScreener

Elranatamab is an off-the-shelf, B-cell maturation antigen CD3-targeted bispecific antibody.

The FDA has extended the review period of the BLA for the chikungunya virus vaccine candidate, VLA1553.

Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK)s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the...

The FDA has accepted for Priority Review the NDA for cefepime-taniborbactam for the treatment of adults with complicated UTI, including pyelonephritis.

Zurzuvae (zuranolone) is understood to be the first and only oral medication indicated to treat adults with postpartum depression (PPD).

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.